Geode Capital Management LLC Grows Position in Pfizer Inc. (NYSE:PFE)

Geode Capital Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 120,589,782 shares of the biopharmaceutical company’s stock after buying an additional 2,923,537 shares during the quarter. Geode Capital Management LLC owned 2.13% of Pfizer worth $3,190,131,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. StoneX Group Inc. raised its stake in Pfizer by 43.5% during the 4th quarter. StoneX Group Inc. now owns 76,031 shares of the biopharmaceutical company’s stock valued at $2,017,000 after buying an additional 23,050 shares during the last quarter. Nemes Rush Group LLC boosted its holdings in Pfizer by 8.7% in the 4th quarter. Nemes Rush Group LLC now owns 126,861 shares of the biopharmaceutical company’s stock worth $3,366,000 after buying an additional 10,189 shares during the period. Mosaic Financial Group LLC purchased a new stake in Pfizer in the 4th quarter worth $208,000. Meridian Investment Counsel Inc. raised its holdings in Pfizer by 3.4% during the fourth quarter. Meridian Investment Counsel Inc. now owns 65,157 shares of the biopharmaceutical company’s stock valued at $1,729,000 after acquiring an additional 2,137 shares during the period. Finally, Summit Financial LLC lifted its position in shares of Pfizer by 147.7% in the fourth quarter. Summit Financial LLC now owns 78,145 shares of the biopharmaceutical company’s stock valued at $2,073,000 after acquiring an additional 46,601 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.6 %

Shares of NYSE PFE opened at $25.36 on Tuesday. The firm has a 50-day simple moving average of $26.05 and a two-hundred day simple moving average of $26.88. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $143.80 billion, a P/E ratio of 17.98, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.